New generation modified azole antifungals against multidrug-resistant Candida auris
Article
Chen, Y., Li, Y., Nahar, K.S., Hasan, Md. M., Marsh, C., Clifford, M., Aleku, G.A., Kelly, S.L., Lamb, D.C., Mpamhanga, C.D., Kounatidis, I., Shah, A., Hind, C.K., Sutton, J.M. and Rahman, K.M. 2025. New generation modified azole antifungals against multidrug-resistant Candida auris . Journal of Medicinal Chemistry. 68 (13), pp. 14054-14071. https://doi.org/10.1021/acs.jmedchem.5c01253
| Type | Article |
|---|---|
| Title | New generation modified azole antifungals against multidrug-resistant Candida auris |
| Authors | Chen, Y., Li, Y., Nahar, K.S., Hasan, Md. M., Marsh, C., Clifford, M., Aleku, G.A., Kelly, S.L., Lamb, D.C., Mpamhanga, C.D., Kounatidis, I., Shah, A., Hind, C.K., Sutton, J.M. and Rahman, K.M. |
| Abstract | The rise of antifungal resistance and limited treatment options highlight the urgent need for new drug classes. Candida auris is a serious global health threat with few effective therapies. In this study, novel azole-based compounds were developed by modifying the azole core with cyclic heteroaliphatic linkers connecting aromatic and heteroaromatic rings. Several compounds showed potent activity against C. auris, including azole-resistant strains, with MICs ranging from 0.016 to 4 µg/mL. The compounds also demonstrated strong activity against C. albicans, Nakaseomyces glabratus, C. tropicalis, and C. parapsilosis, with MICs mostly below 1 µg/mL. Compounds 7, 18, and 21 were more potent than fluconazole. Compound 7 inhibited CYP51, eradicated C. auris biofilms, and showed better intracellular accumulation than fluconazole. In vivo studies in Galleria mellonella and Drosophila melanogaster confirmed efficacy at 5 mg/kg and no toxicity up to 50 mg/kg, supporting further development of this scaffold against multidrug-resistant C. auris infections. |
| Keywords | Candida auris; antifungals; fluconazole |
| Sustainable Development Goals | 3 Good health and well-being |
| Middlesex University Theme | Health & Wellbeing |
| Research Group | Antimicrobial Resistance |
| Publisher | American Chemical Society |
| Journal | Journal of Medicinal Chemistry |
| ISSN | 0022-2623 |
| Electronic | 1520-4804 |
| Publication dates | |
| Online | 23 Jun 2025 |
| 10 Jul 2025 | |
| Publication process dates | |
| Submitted | 06 May 2025 |
| Accepted | 11 Jun 2025 |
| Deposited | 16 Jun 2025 |
| Output status | Published |
| Publisher's version | License File Access Level Open |
| Copyright Statement | © 2025 The Authors. Published by American Chemical Society. This publication is licensed under CC-BY 4.0 https://creativecommons.org/licenses/by/4.0/ |
| Digital Object Identifier (DOI) | https://doi.org/10.1021/acs.jmedchem.5c01253 |
| PubMed ID | 40550788 |
| PubMed Central ID | 12257509 |
| Web of Science identifier | WOS:001518419500001 |
| Language | English |
https://repository.mdx.ac.uk/item/263934
Download files
Publisher's version
| chen-et-al-2025-new-generation-modified-azole-antifungals-against-multidrug-resistant-candida-auris.pdf | ||
| License: CC BY 4.0 | ||
| File access level: Open | ||
175
total views36
total downloads5
views this month0
downloads this month